Clinical Trial Update: Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing IPX054 with immediate-release and controlled-release carbidopa-levodopa in Parkinson's disease completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Parkinson Disease
• Parkinson Disease

Drugs mentioned

• Carbidopa-levodopa (CR) (carbidopa-levodopa)
• Carbidopa-levodopa (IR) (carbidopa-levodopa)
• IPX054 (IPX054)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Idiopathic Parkinson's Disease | Phase 2 | Status: COMPLETED